Stephen Hoffman | Chief Executive And Scientific Officer

Stephen Hoffman, Chief Executive And Scientific Officer, Sanaria

Dr. Hoffman is the founder, chief executive and scientific officer of Sanaria Inc., a company dedicated to developing a whole sporozoite (PfSPZ) malaria vaccine to halt transmission of and eliminate malaria, and chairman, Protein Potential LLC, a company focused on developing vaccines for shigellosis, enterotoxigencic E. coli diarrhea, and typhoid fever. From 1980-1984 he was chief of clinical investigation at NAMRU-2 in Jakarta, Indonesia. From 1987-2000 he was malaria program director, Naval Medical Research Center, where his team were leaders in subunit malaria vaccine development and sequencing the Plasmodium falciparum genome and published the first studies in the world showing DNA vaccines elicited killer T cells in humans. In 2000 he joined Celera Genomics as Sr. VP Biologics and created a program to 1) utilize genomics and proteomics to produce immunotherapeutics and cancer vaccines, initiating the field of personalized (precision) medicine, and 2) sequence the genome of the mosquito, Anopheles gambiae. He has held several professorships, chairs or serves on multiple advisory boards, is past president of the American Society of Tropical Medicine and Hygiene, authored > 450 scientific publications, and has numerous patents. He is the most highly cited author in the world for scientific papers on malaria published between 1995 and 2005, was listed as the third most influential person in the world vaccine industry in 2015 when he received the Vaccine Industry Excellence Award for Best Biotech CEO.  He received his BA from the University of Pennsylvania, MD from Cornell, and Diploma in Tropical Medicine and Hygiene from London School of Hygiene and Tropical Medicine and completed residency training at UC San Diego. He was elected to membership in the National Academy of Medicine in 2004 and received the Distinguished Alumni Award from Weill Cornell Medical College in 2016.


Pre-congress Workshops, April 6 @ 10:00


The enthusiasm for investing in biologics, including vaccines, has grown significantly over the last decade with the advent of novel platform technologies and new therapeutic modalities but raising capital remains a challenge.Topics include:
  • What is the average cost and time to develop a new vaccine?
  • How have biotechs raised money when they don’t have access to these funds? How was it done? How hard was it? (Sanaria)
  • Funding needs and research and development gaps for achieving vaccine research and development preparedness targets
  • Promoting private investment in vaccine development

Day 2, April 8 @ 11:40

New trial data from Malaria

last published: 05/Mar/20 10:35 GMT

back to speakers

Sign Up for Event Updates